NEW YORK (TheStreet) -- Shares of Zeltiq Aesthetics (ZLTQ) are falling by 6.95% to $26.11 on heavy trading volume on Wednesday afternoon, after the Pleasanton, CA-based company posted a loss for the 2016 first quarter.
After yesterday's market close, the medical technology company reported a net loss of 25 cents per share, in line with analysts' expectations. Last year, Zeltiq posted a loss of 6 cents per share.
Revenue jumped by 25% to $64.5 million year-over-year and was higher than analysts' estimates of $61.8 million.
"Our first quarter results reflect the positive impact of our national direct to consumer (DTC) campaign and further validate our beliefs regarding the significant number of patients that are searching for a non-invasive fat reduction treatment," CEO Mark Foley said in a statement.
For fiscal 2016, Zeltiq forecasts revenue between $320 million and $325 million, up from its previous outlook of about $315 million.
Analysts are looking for revenue of $316.3 million for the full year.
About 1.39 million of the company's shares have changed hands so far today vs. its average volume of 604,958 shares per day.
Separately, TheStreet Ratings Team has a "Buy" rating with a score of B- on the stock.
The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, compelling growth in net income and expanding profit margins.
The team believes its strengths outweigh the fact that the company shows weak operating cash flow.
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
You can view the full analysis from the report here: ZLTQ